ClinicalTrials.gg

Program

AZD3974

A development code.

Its studies are led by AstraZeneca.

Furthest: phase 1, since Dec 5, 20251 company-led study, 1 open or runningNext primary completion: Dec 8, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca11 open or runningphase 1since Dec 5, 2025Dec 5, 2025Dec 8, 2026phase 1 · NCT07290283
  • Named in AstraZeneca’s own pipeline as AZD3974, phase 1, as of Oct 30, 2026 (source).

Also a collaborator on its studies: parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 5, 2025First study: phase 1 study in Healthy ParticipantsFirst studyNCT07290283 · 176 planned · United States

Ahead

  1. Dec 8, 2026Primary completion: phase 1 study in Healthy ParticipantsNCT07290283

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07290283Healthy Participants · United States1RecruitingDec 8, 2026176

How it is read

Names in the registry

  • “AZD3974”, 1 entry

Codes read as this program: AZD3974.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.